IHM
Iguana Healthcare Management Portfolio holdings
AUM
$133M
This Quarter Return
+27.08%
1 Year Return
+45.66%
3 Year Return
+127.07%
5 Year Return
–
10 Year Return
–
AUM
$481M
AUM Growth
+$481M
(+121%)
Cap. Flow
+$232M
Cap. Flow
% of AUM
48.2%
Top 10 Holdings %
Top 10 Hldgs %
40.64%
Holding
93
New
17
Increased
41
Reduced
5
Closed
21
Top Buys
| 1 |
CLVS
Clovis Oncology, Inc.
CLVS
|
$20.2M |
| 2 |
Ultragenyx Pharmaceutical
RARE
|
$18.4M |
| 3 |
Biogen
BIIB
|
$13.3M |
| 4 |
MDCO
Medicines Co
MDCO
|
$12.8M |
| 5 |
Amgen
AMGN
|
$12.5M |
Top Sells
| 1 |
Baxter International
BAX
|
$6.11M |
| 2 |
HCA Healthcare
HCA
|
$3.85M |
| 3 |
Illumina
ILMN
|
$3.51M |
| 4 |
Elevance Health
ELV
|
$2.51M |
| 5 |
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
|
$2.1M |
Sector Composition
| 1 | Healthcare | 85.28% |
| 2 | Energy | 1% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Ultragenyx Pharmaceutical
RARE
$2.89B
| $28.4M | 5.06% |
400,000
+260,000
| +186% | +$18.4M |
|
|
CLVS
2
DELISTED
Clovis Oncology, Inc.
CLVS
| $23.4M | 4.18% |
650,000
+560,000
| +622% | +$20.2M |
|
3
Zimmer Biomet
ZBH
$21B
| $22.1M | 3.94% |
170,000
+70,000
| +70% | +$9.1M |
|
|
4
Biogen
BIIB
$19.4B
| $20.3M | 3.63% |
65,000
+42,500
| +189% | +$13.3M |
|
|
ALXN
5
DELISTED
Alexion Pharmaceuticals Inc
ALXN
| $18.4M | 3.28% |
150,000
+100,000
| +200% | +$12.3M |
|
|
6
Amgen
AMGN
$155B
| $18.4M | 3.27% |
110,000
+75,000
| +214% | +$12.5M |
|
7
Pfizer
PFE
$141B
| $16.9M | 3.02% |
500,000
+300,000
| +150% | +$10.2M |
|
|
OMED
8
DELISTED
OncoMed Pharmaceuticals, Inc.
OMED
| $16.6M | 2.95% |
1,450,000
+817,800
| +129% | +$9.35M |
|
|
CELG
9
DELISTED
Celgene Corp
CELG
| $15.7M | 2.8% |
150,000
+25,000
| +20% | +$2.61M |
|
|
MDCO
10
DELISTED
Medicines Co
MDCO
| $15.1M | 2.69% |
400,000
+340,000
| +567% | +$12.8M |
|
|
GBT
11
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $15M | 2.67% |
650,000
+350,000
| +117% | +$8.07M |
|
|
NUVA
12
DELISTED
NuVasive, Inc.
NUVA
| $13.3M | 2.38% |
200,000
+100,000
| +100% | +$6.67M |
|
|
SHPG
13
DELISTED
Shire pic
SHPG
| $12.6M | 2.25% |
65,000
+5,000
| +8% | +$969K |
|
|
AERI
14
DELISTED
Aerie Pharmaceuticals, Inc.
AERI
| $12.5M | 2.22% |
330,000
+180,000
| +120% | +$6.79M |
|
|
MZOR
15
DELISTED
Mazor Robotics Ltd.
MZOR
| $10.3M | 1.84% |
400,000
+200,000
| +100% | +$5.17M |
|
16
Alnylam Pharmaceuticals
ALNY
$58.5B
| $10.2M | 1.81% |
150,000
+125,000
| +500% | +$8.47M |
|
|
DERM
17
DELISTED
Dermira, Inc.
DERM
| $10.1M | 1.81% |
300,000
+150,000
| +100% | +$5.07M |
|
18
Gilead Sciences
GILD
$140B
| $9.49M | 1.69% |
120,000
-15,000
| -11% | -$1.19M |
|
19
Merck
MRK
$210B
| $9.36M | 1.67% |
150,000
+25,000
| +20% | +$1.56M |
|
20
Glaukos
GKOS
$5.5B
| $9.06M | 1.61% |
240,000
+105,000
| +78% | +$3.96M |
|
21
Exelixis
EXEL
$10.1B
| $8.95M | 1.6% |
700,000
+350,000
| +100% | +$4.48M |
|
|
TVTY
22
DELISTED
Tivity Health, Inc. Common Stock
TVTY
| $8.73M | 1.56% |
330,000
+105,000
| +47% | +$2.78M |
|
23
Supernus Pharmaceuticals
SUPN
$2.53B
| $7.42M | 1.32% |
300,000
+75,000
| +33% | +$1.86M |
|
24
Bristol-Myers Squibb
BMY
$96B
| $7.01M | 1.25% |
+130,000
| New | +$7.01M |
|
25
Merus
MRUS
$4.98B
| $6.7M | 1.19% |
400,000
+200,000
| +100% | +$3.35M |
|